Targeting drug delivery within the suprachoroidal space

Drug Discovery Today - Tập 24 - Trang 1654-1659 - 2019
Jae Hwan Jung1, J. Jeremy Chae1, Mark R. Prausnitz1
1School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA

Tài liệu tham khảo

Huang, 2018, Overcoming ocular drug delivery barriers through the use of physical forces, Adv. Drug Deliv. Rev., 126, 96, 10.1016/j.addr.2017.09.008 Kaji, 2018, Drug delivery devices for retinal diseases, Adv. Drug Deliv. Rev., 128, 148, 10.1016/j.addr.2017.07.002 Peynshaert, 2018, In vitro and ex vivo models to study drug delivery barriers in the posterior segment of the eye, Adv. Drug Deliv. Rev., 126, 44, 10.1016/j.addr.2017.09.007 Chiang, 2018, The suprachoroidal space as a route of administration to the posterior segment of the eye, Adv. Drug Deliv. Rev., 126, 58, 10.1016/j.addr.2018.03.001 Thakur Singh, 2017, Minimally invasive microneedles for ocular drug delivery, Expert Opin. Drug Deliv., 14, 525, 10.1080/17425247.2016.1218460 Barar, 2016, Advanced drug delivery and targeting technologies for the ocular diseases, Bioimpacts, 6, 49, 10.15171/bi.2016.07 Kim, 2014, Ocular delivery of macromolecules, J. Control. Release, 190, 172, 10.1016/j.jconrel.2014.06.043 Moisseiev, 2016, The suprachoroidal space: From potential space to a space with potential, Clin. Ophthalmol., 10, 173, 10.2147/OPTH.S89784 Rai Udo, 2015, The suprachoroidal pathway: A new drug delivery route to the back of the eye, Drug Discov. Today, 20, 491, 10.1016/j.drudis.2014.10.010 Christian, J. et al. iScience Surgical Corp. Composite ophthalmic microcannula. US7207980B2. Wellik, 2015, A review of the istent((r)) trabecular micro-bypass stent: Safety and efficacy, Clin. Ophthalmol., 9, 677, 10.2147/OPTH.S57217 Malvankar-Mehta, 2015, Istent as a solo procedure for glaucoma patients: a systematic review and meta-analysis, PLoS ONE, 10, 10.1371/journal.pone.0128146 Hoh, 2014, Two-year clinical experience with the cypass micro-stent: safety and surgical outcomes of a novel supraciliary micro-stent, Klin. Monbl. Augenheilkd., 231, 377, 10.1055/s-0034-1368214 Patel, 2016, Targeted drug delivery within the eye through the suprachoroidal space, J. Ocul. Pharmacol. Ther., 32, 640, 10.1089/jop.2016.0158 Patel, 2012, Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye, Invest. Ophthalmol. Vis. Sci., 53, 4433, 10.1167/iovs.12-9872 Patel, 2011, Suprachoroidal drug delivery to the back of the eye using hollow microneedles, Pharm. Res., 28, 166, 10.1007/s11095-010-0271-y Gilger, 2013, Treatment of acute posterior uveitis in a porcine model by injection of triamcinolone acetonide into the suprachoroidal space using microneedles, Invest. Ophthalmol. Vis. Sci., 54, 2483, 10.1167/iovs.13-11747 Jung, 2018, Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle, J. Control. Release, 277, 14, 10.1016/j.jconrel.2018.03.001 Jung, 2018, Targeted drug delivery in the suprachoroidal space by swollen hydrogel pushing, Invest. Ophthalmol. Vis. Sci., 59, 2069, 10.1167/iovs.17-23758 Kim, 2015, Formulation to target delivery to the ciliary body and choroid via the suprachoroidal space of the eye using microneedles, Eur. J. Pharm. Biopharm., 95, 398, 10.1016/j.ejpb.2015.05.020 Kim, 2014, Particle-stabilized emulsion droplets for gravity-mediated targeting in the posterior segment of the eye, Adv. Healthc. Mater., 3, 1272, 10.1002/adhm.201300696 Kim, 2014, Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles, Invest. Ophthalmol. Vis. Sci., 55, 7387, 10.1167/iovs.14-14651 Goldstein, 2016, Suprachoroidal corticosteroid administration: a novel route for local treatment of noninfectious uveitis, Transl. Vis. Sci. Technol., 5, 14, 10.1167/tvst.5.6.14 Suprachoroidal injection of CLS-TA in subjects with macular edema associated with non-infectious uveitis (peachtree). https://clinicaltrials.gov/ct2/show/NCT02595398 [accessed February 19, 2019]. Suprachoroidal injection of CLS-TA in subjects non-infectious uveitis (azalea). https://clinicaltrials.gov/ct2/show/NCT03097315 [accessed February 19, 2019]. Suprachoroidal injection of CLS-TA alone or with aflibercept in subjects with diabetic macular edema (hulk). https://clinicaltrials.gov/ct2/show/NCT02949024 [accessed February 19, 2019]. Patel, 2006, Suprachoroidal silicone oil: recognition and possible mechanisms, Eye, 20, 854, 10.1038/sj.eye.6702029 Bressler, 2011, Panretinal photocoagulation for proliferative diabetic retinopathy, N. Engl. J. Med., 365, 1520, 10.1056/NEJMct0908432 Chappelow, 2012, Panretinal photocoagulation for proliferative diabetic retinopathy: Pattern scan laser versus argon laser, Am. J. Ophthalmol., 153, 137, 10.1016/j.ajo.2011.05.035 Holz, 2014, Recent developments in the treatment of age-related macular degeneration, J. Clin. Invest., 124, 1430, 10.1172/JCI71029 Rowe-Rendleman, 2014, Drug and gene delivery to the back of the eye: From bench to bedside, Invest. Ophthalmol. Vis. Sci., 55, 2714, 10.1167/iovs.13-13707 Syed, 2012, Wet AMD market, Nat. Rev. Drug Discov., 11, 827, 10.1038/nrd3790 Ghate, 2008, Barriers to glaucoma drug delivery, J. Glaucoma, 17, 147, 10.1097/IJG.0b013e31814b990d Ethier, 2004, Ocular biomechanics and biotransport, Annu. Rev. Biomed. Eng., 6, 249, 10.1146/annurev.bioeng.6.040803.140055 Falavarjani, 2013, Adverse events and complications associated with intravitreal injection of anti-vegf agents: a review of literature, Eye, 27, 787, 10.1038/eye.2013.107 Del Amo, 2008, Current and future ophthalmic drug delivery systems. A shift to the posterior segment, Drug Discov. Today, 13, 135, 10.1016/j.drudis.2007.11.002 Prausnitz, 2008, Transdermal drug delivery, Nat. Biotechnol., 26, 1261, 10.1038/nbt.1504 Gungor, 2010, Trans-scleral iontophoretic delivery of low molecular weight therapeutics, J. Control. Release, 147, 225, 10.1016/j.jconrel.2010.07.107 Eljarrat-Binstock, 2006, Iontophoresis: a non-invasive ocular drug delivery, J. Control. Release, 110, 479, 10.1016/j.jconrel.2005.09.049 Calo, 2015, Biomedical applications of hydrogels: a review of patents and commercial products, Eur. Polym. J., 65, 252, 10.1016/j.eurpolymj.2014.11.024 Hoare, 2008, Hydrogels in drug delivery: progress and challenges, Polymer, 49, 1993, 10.1016/j.polymer.2008.01.027 Hoffman, 2012, Hydrogels for biomedical applications, Adv. Drug Deliv. Rev., 64, 18, 10.1016/j.addr.2012.09.010 Burdick, 2011, Hyaluronic acid hydrogels for biomedical applications, Adv. Mater., 23, H41, 10.1002/adma.201003963 Fraser, 1997, Hyaluronan: Its nature, distribution, functions and turnover, J. Intern. Med., 242, 27, 10.1046/j.1365-2796.1997.00170.x Strom, 2015, Preparation and physical properties of hyaluronic acid-based cryogels, J. Appl. Polym. Sci., 132, 42194, 10.1002/app.42194 Kleinberg, 2011, Vitreous substitutes: a comprehensive review, Surv. Ophthalmol., 56, 300, 10.1016/j.survophthal.2010.09.001 Weinberger, 1998, Long-term follow-up of perfluorocarbon liquid in the anterior chamber, Retina, 18, 233, 10.1097/00006982-199803000-00007 Liu, 2006, Encapsulated ultrasound microbubbles: therapeutic application in drug/gene delivery, J. Control. Release, 114, 89, 10.1016/j.jconrel.2006.05.018 Pickering, 1907, Cxcvi.—emulsions, J. Chem. Soc. Trans., 91, 2001, 10.1039/CT9079102001 Aveyard, 2003, Emulsions stabilised solely by colloidal particles, Adv. Colloid Interface Sci., 100–102, 503, 10.1016/S0001-8686(02)00069-6 Csukas, 1992, Prostaglandin e2 binding site distribution and subtype classification in the rabbit iris-ciliary body, Prostaglandins, 44, 199, 10.1016/0090-6980(92)90013-J Toris, 2008, Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction, Surv. Ophthalmol., 53, S107, 10.1016/j.survophthal.2008.08.010 Urtti, 2006, Challenges and obstacles of ocular pharmacokinetics and drug delivery, Adv. Drug Deliv. Rev, 58, 1131, 10.1016/j.addr.2006.07.027 Kaur, 2004, Vesicular systems in ocular drug delivery: an overview, Int. J. Pharm., 269, 1, 10.1016/j.ijpharm.2003.09.016 Bhatt, 2005, Prospective survey of adverse reactions to topical antiglaucoma medications in a hospital population, Eye, 19, 392, 10.1038/sj.eye.6701515 Reardon, 2011, Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review, Patient Pref. Adher., 5, 441, 10.2147/PPA.S23780 Chiang, 2016, Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma, J. Control. Release, 228, 48, 10.1016/j.jconrel.2016.02.041 Hovakimyan, 2015, Development of an experimental drug eluting suprachoroidal microstent as glaucoma drainage device, Transl. Vis. Sci. Technol., 4, 14, 10.1167/tvst.4.3.14 Chen, 2015, Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model, J. Control. Release, 203, 109, 10.1016/j.jconrel.2015.02.021